Androgen deprivation cuts lung cancer risk in prostate cancer patients

04/15/2013 | Family Practice News

Researchers examined data from the Veterans Affairs Central Cancer Registry and found that men with prostate cancer who received androgen blockade therapy had an 18% lower risk of developing a secondary lung cancer than those who didn't get such treatment. The findings were presented at the annual meeting of the American Association for Cancer Research.

View Full Article in:

Family Practice News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA